Trial Profile

An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics; Methotrexate
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms TOZURA
Sponsors Roche

19 Aug 2021 (3591074) Full text isn't accessible.
16 Jun 2018 Results (n=100) presented at the 19th Annual Congress of the European League Against Rheumatism.
06 Apr 2018 Results (n=1804) of pooled data from 11 clinical trials assessing the efficacy, safety and immunogenicity of TCZ-SC 162 mg qw as monotherapy and in combination with csDMARDs over 24 weeks in adult patients with moderate to severe RA in a broad geographic setting, were published in the Rheumatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com